Zhenbaodao released its 2026 interim report. During the reporting period, the company's total operating revenue was 296 million yuan, down 58.60% year-on-year. Net profit attributable to the parent company was negative 271 million yuan, a decrease of 193 million yuan compared with the same period last year, with the loss widening. Net cash inflow from operating activities was 103 million yuan. The asset-liability ratio was 41.08%, gross margin was 5.53%, ROE was negative 4.51%, and diluted earnings per share was negative 0.29 yuan. The number of shareholders was 31,000, and the top ten shareholders held 62.54% of total share capital.
Heilongjiang ZBD Pharmaceutical Co LtdNet loss widened to 271 million yuan with revenue down 58.6%.